

January 28, 2016

**BSE Limited**  
Corporate Service Department  
1st Floor, New Trading Ring  
Rotunda Building, P.J.Tower  
Dalal Street, Fort  
Mumbai - 400 001

**The National Stock Exchange of India Ltd.**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E)  
Mumbai – 400 051

Dear Sirs,

**Sub: Schedule of Investor Conference Call for Jubilant Life Sciences Limited –  
Unaudited Financial Results for the quarter ended December 31, 2015**

Pursuant to Regulation 30 of the Listing Regulations, we wish to inform you that the Company is organising a Conference Call on February 9, 2016 post declaration of Financial results for the quarter ended December 31, 2015 to Stock Exchanges. The details of Conference Call are attached.

Kindly acknowledge receipt of the same.

Thanking you,

Yours faithfully,  
For Jubilant Life Sciences Limited

  
Rajiv Shah  
Company Secretary



Encl.: as above

**A Jubilant Bhartia Company**

OUR VALUES



**Jubilant Life Sciences Limited**  
1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubl.com

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223,  
UP, India  
CIN : L24116UP1978PLC004624



Noida, Thursday, January 28, 2016

## Conference call on Tuesday, February 09, 2016 at 05:00 pm IST

The management team of Jubilant Life Sciences Limited (Jubilant) – an integrated global pharmaceutical and life sciences company will host a **conference call for analysts and investors on Tuesday, February 09, 2016 at 05:00 pm IST**. The call will commence with a brief management discussion on the financial performance for the quarter ended December 31<sup>st</sup>, 2015, followed by an interactive Question & Answer session.

Mr. Shyam S. Bhartia, Chairman, Mr. Hari S. Bhartia, Co-Chairman & Managing Director, Mr. R Sankaraiah, Executive Director – Finance, Mr. Ravi Agrawal, Head - Investor Relations and Mr. Anupam Jain, Manager – Investor Relations, Jubilant Life Sciences Limited, will represent the management team at the conference call.

Conference Dial-In Numbers	
<b>Primary Number:</b>	<b>+91 22 3938 1071</b>
<b>Secondary Number:</b>	<b>+91 22 6746 8354</b>
<i>The numbers listed above are universally accessible from all networks and all countries.</i>	
<b>Local Access Number:</b>	<b>6000 1221</b> <i>Available in – Ahmedabad, Bengaluru, Chennai, Cochin, Delhi, Gurgaon, Hyderabad, Kolkata, Noida. Accessible from all major carriers except BSNL/MTNL.</i>
<b>Local Access Number:</b>	<b>3940 3977</b> <i>Available in - Ahmedabad, Bengaluru, Chandigarh, Chennai, Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Pune, Lucknow. Accessible from all carriers.</i>
<b>Toll Free Number:</b>	USA: <b>1 866 746 2133</b> UK: <b>0 808 101 1573</b> Singapore: <b>800 101 2045</b> Hong Kong: <b>800 964 448</b>

---

**Replay facility available from Feb 09 to 16, 2016**

**Dial in No.: +91 22 3065 2322**  
**Playback ID: 74506#**

---

**-ENDS -**

## About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery Solutions. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 12 world-class manufacturing facilities in India, US and Canada and a team of about 6,100 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).

### For more information please contact:

Ravi Agrawal / Anupam Jain  
Jubilant Life Sciences Limited  
Ph: +91-120 4361002 / 21  
E-mail: ravi\_agrawal@jubl.com  
anupam\_jain@jubl.com

Siddharth Rangnekar / Karl Kolah  
CDR India  
Ph: +91-22 6645 1209 / 20  
E-mail: siddharth@cdr-india.com  
karl@cdr-india.com

**Disclaimer:** Statements made on the call relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.